Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.
Confronted by Trump, Denmark Looks to Its European Neighbors for Support
The prime minister does a European tour while announcing more spending on security around the island, following President Trump’s stated desire to have Greenland, a semiautonomous Danish territory, as part of the U.
Outsourcing-pharma1d
Novo Nordisk’s next-generation obesity drug shows promise in early clinical trials
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are planned.
Denmark boosts Arctic defence spending by $2.1 billion, responding to US pressure
Denmark said on Monday it would spend 14.6 billion Danish crowns ($2.05 billion) boosting its military presence in the Arctic, following renewed interest by U.S. President Donald Trump in controlling Greenland,
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
THESE MEDICATIONS ARE MOSTLY KNOWN FOR TREATING DIABETES AND OBESITY.. BUT THE F-D-A HAS APPROVED THEM FOR PREVENTING HEART DISEASE AFTER STUDIES LAST FALL. THAT SHOWED ABOUT A 20% REDUCTION IN CARDIOVASCULAR EVENTS DR.
Bureau of Meteorology1d
Denmark Forecast
Partly cloudy. Slight chance of a shower in the south this morning. Near zero chance of rain elsewhere. Winds southerly 15 to 25 km/h turning southeasterly 20 to 30 km/h in the afternoon. Daytime maximum temperatures 23 to 28. Mostly sunny. Winds east to ...
ENDPOINTS NEWS5d
No­vo Nordisk’s amy­cretin prompts 22% weight loss in ear­ly obe­si­ty tri­al
Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical trial, the Danish company said Friday.
Next-gen Novo Nordisk shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.
Novo Nordisk shares surge on results of new obesity drug trial
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share price on Friday. View on euronews
The Financial Times1d
Donald Trump in fiery call with Denmark’s prime minister over Greenland
was $540 now $319 for your first year Make up your own mind. Build robust opinions on the FT's trusted journalism. Offer available until 27 February 2025.
The New York Times2d
New York Times - Top Stories
Stocks Sink as Investors Worry About China’s A.I. Advances A jolt of panic hit technology stocks on Monday, with investors rattled by fears that A.I. advances by Chinese upstarts could threaten ...
Novo Nordisk A/S: Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly